Barely Significant
← all excerpts

Triple negative breast cancer: looking for the missing link between biology and treatments.

Oncotarget · 2015 · PMC4694936 · PMID 26387133

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

reached borderline significanceP = 0.06so close (0.05 < p ≤ 0.1)
A retrospective analysis from the MA5 Trial, randomly assigning patients to receive either CMF or CEF adjuvant chemotherapy, showed an increased 5-year DFS for the former (71% versus 51%, respectively) among patients with Basal-like breast cancer (BLBC); the test for interaction between Basal-like phenotype and treatment arm reached borderline significance ( P = 0.06) indicating that patients with TNBC may not derive a particular benefit from anthracyclines [ 48 ].

also in 370 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.